Anergis   Report issue

For profit Phase 2
Founded: Epalinges Switzerland (2001)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2008
NCT01719133
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

birch allergen (5 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Conjunctivitis (Phase 2)

Conjunctivitis, Allergic (Phase 2)

Hypersensitivity (Phase 2)

Rhinitis (Phase 2)

Rhinitis, Allergic (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 1